{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"2.9","value":"2.7"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"2.9","value":"2.8"},{"groupId":"OG002","lowerLimit":"1.2","upperLimit":"4.2","value":"2.6"},{"groupId":"OG003","lowerLimit":"1.2","upperLimit":"3.1","value":"2.7"},{"groupId":"OG004","lowerLimit":"1.2","upperLimit":"3.1","value":"1.6"},{"groupId":"OG005","lowerLimit":"1.4","upperLimit":"2.9","value":"2.2"},{"groupId":"OG006","lowerLimit":"1.2","upperLimit":"2.8","value":"1.4"},{"comment":"The 95% confidence interval was not calculable due to insufficient number of participants with events.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"3.0"},{"groupId":"OG008","lowerLimit":"1.2","upperLimit":"2.9","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"67"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"23"}],"units":"Participants"}],"description":"Time to response (TTR) by independent central review was defined as the time interval between the date of registration until the date at which the criteria were first met for complete response (CR) or partial response (PR). Only participants who achieved CR or PR were included in the TTR analysis. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. HER2-positive other solid tumors included participants with salivary/submandibular/parotid gland (8 participants), breast with HER2-mutation (2 participants), endometrial (2 participants), esophageal (2 participants), Paget's disease (2 participants), cholangiocarcinoma (1 participant), extraskeletal myxoide chondrosarcoma (1 participant), gallbladder (1 participant), pancreatic (1 participant), small intestine (1 participant), uterine cervix (1 participant) and HER2-low gastric/GEJ (1 participant who received 5.4 mg/kg) cancer.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG000","title":"Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg"},{"description":"Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG001","title":"Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg"},{"description":"Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG002","title":"Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg"},{"description":"Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG003","title":"Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg"},{"description":"Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG004","title":"Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg"},{"description":"Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG005","title":"Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg"},{"description":"Participants with HER2-expressing NSCLC tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG006","title":"Dose Expansion: HER2-expressing NSCLC Tumors"},{"description":"Participants with HER2-expressing colorectal tumors received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG007","title":"Dose Expansion: HER2-expressing Colorectal Tumors"},{"description":"Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG008","title":"Dose Expansion: HER2-expressing Other Solid Tumors"}],"paramType":"MEDIAN","populationDescription":"Time to response was assessed among participants who achieved CR or PR in the Intent-to-Treat Analysis Set.","reportingStatus":"POSTED","timeFrame":"From 6 months postdose of last participant up to 3 years 5 months","title":"Time to Response (TTR) Following Treatment With DS-8201a in Participants With Advanced Solid Malignant Tumors (Dose Expansion Phases)","type":"SECONDARY","unitOfMeasure":"months"}